Released May 8, 2025, after the close
10-Q filed May 8, 2025, 38 days after period end · 0000950170-25-067072
Q1 2025 · 10-Q
Revenue$17.40M$17.40M +33.8% vs Q1 2024+17.5% vs Q4 2024
Net Income-$75.97M-$75.97M N/M vs Q1 2024N/M vs Q4 2024
EPS Diluted-$9.08-$9.08 N/M vs Q1 2024no prior Q4 2024 on file
Operating Income-$68,514,000N/M
Operating Cash Flow-$67,883,000N/M
Margins · derived
Operating margin-393.8%+41.3 pt vs Q1 2024
Net margin-436.6%+10.9 pt vs Q1 2024
What the release said
The release
Same quarter
| Metric | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 |
|---|---|---|---|---|
| Revenue | $17.40M | $13.01M | $12.67M | $5.90M |
| Net Income | -$75.97M | -$58.21M | -$50.05M | -$39.11M |
| EPS Diluted | -$9.08 | -$0.59 | -$0.85 | -$0.84 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR